anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
JNJ-26854165 is a new drug in development and belongs to a class of drugs that act on the specific protein present in cells. It may stop cancer cells from growing or kill cancer cells. In this study, the safety (the effect on the body) of the JNJ-26854165 in patients with advanced or refractory solid tumors will be examined. The effect (if any) of JNJ-26854165 on the disease will be assessed throughout the study. The maximum dose tolerated by these patients will be determined.

The dose of JNJ 26854165 will start low and will be increased during the study. The drug will be taken by mouth every day in each 21-day cycle. The dose each patient receives will be assigned at enrollment. Patients who enroll at a later time may receive a higher dose. If patients do not have severe side effects at a certain dose level, the next group of 3 to 6 patients will get a higher dose. The dose will increase until some patients have severe side effects. The dose will be then decreased and 3 to 6 patients will receive the highest amount of drug where non-severe side effects were observed.

The amount of JNJ 26854165 in the blood will be measured and the effect of JNJ 26854165 on the disease will also be monitored. The effect of food on the absorption, break down and elimination of the drug will be studied in some patients. At some dose levels, the possible interaction of JNJ 26854165 with medications frequently used in cancer patients will be examined and patients at these dose levels will be asked to take a single dose of three additional drugs (dextromethorphan hydrobromide (30mg), tolbutamide (250mg), and midazolam (5mg) "cocktail") on 2 study days, which will all be supplied by the study doctor.

Patients will be screened for eligibility up to 4 weeks before the study drug is administered. During Cycle 1 patients will be observed as inpatients for at least 12 hours after administration of the drug on 3 or 4 days and will be required to visit the study site on 2 additional days. One additional visit is required for patients in whom the food effect or interaction with other medications will be examined. During Cycle 2, patients are required to visit the study center on 2 days. During all cycles after Cycle 2, patients are required to visit the study center on 1 day. Fourteen days after the last dose of JNJ-26854165, the patient will be invited for a follow-up visit which will include tests for safety and the effect of the drug on the disease. The proposed starting dose of JNJ-26854165 is 4 mg/day as a single oral dose. JNJ26854165 will be provided in a glass vial with tear-off cap placed in a child resistant pouch so that the drug may be taken at home. Patients will take JNJ-26854165 each day while in the study. Treatment may continue as long as there is benefit and there are no unacceptable side effects as assessed by the study doctor.
The present invention provides a traditional Chinese medicine composition for treatment of acute mastitis. The traditional Chinese medicine composition comprises, by weight, 3-4 parts of ligusticum chuanxiong hort, 6-8 parts of dandelion, 3-4 parts of medicated leaven, 2-4 parts of vitis vinifera, 3-4 parts of gentian, 6-8 parts of radix bupleuri, 8-10 parts of pseudobulubs cremastrae seu pleiones, 2-4 parts of radix codonopsis, 3-5 parts of licorice, 5-6 parts of radix scrophulariae, 1-3 parts of frankincense, 10-15 parts of vegetable sponge of luffa, 4-5 parts of herb of klein cinquefoil, 2-4 parts of Japanese raspberry herb, 3-5 parts of sargentgloryvine stem, 4-6 parts of hyrtanandra hirta miq, 3-4 parts of melinis repens, 2-4 parts of huguenot fern herb and 1-3 parts of aristolochia debilis sieb. The traditional Chinese medicine composition has convenient preparation and usage. The traditional Chinese medicine composition is safe without side effect, and has effects of clearing heat and removing toxin], replenishing qi and nourishing blood, strengthening and heat damping, and the like. The traditional Chinese medicine composition has substantial effect on acute mastitis. Most of the treatments of the traditional Chinese medicine composition achieve the effect by years of clinical practice. The traditional Chinese medicine composition has effect of simultaneous treatment of principal and subordinate symptoms.
A method for treatment of an animal for systemic hypotension induced by internal nitric oxide production caused by endotoxin or cytokines. The method involves administering an α1 adrenergic agonist and an amount of an inhibitor of nitric oxide formation from arginine restoring vascular contractile sensitivity to $(a)1 adrenergic agonists. Preferable NG-substituted arginine (having at least one hydrogen on a guanidino amino group replaced by another atomic or molecular species). The inhibitor is administered to an animal having such induced systemic hypotension. Arginine derivative inhibitors are preferably of the L configuration and include pharmaceutically acceptable addition salts. Treatment of systemic hypotension in a patient which has been induced by chemotherapy with biologic response modifiers such as tumor necrosis factor or interleukin-2 may be likewise accomplished. Treatment of an animal for systemic hypotension induced by endotoxin, or other bacterial toxins, e.g., septic shock, may also be accomplished by treatment with α¿1? adrenergic agonists and an inhibitor such as an arginine derivative, restoring vascular contractile sensitivity to the α1 adrenergic agonists.
OBJECTIVES: Perioperative bleeding poses a significant issue during thoracic surgery. Tranexamic acid (TXA) is one of the most commonly used antifibrinolytic agents for surgical patients. The purpose of the current study was designed to investigate the efficacy and safety of TXA in patients undergoing thoracic surgery.
METHODS: An extensive search of PubMed, Web of Science (WOS), Cochrane Library (trials), Embase, OVID, China National Knowledge Infrastructure (CNKI), Wanfang, and VIP electronic databases was performed to identify studies published between the inception of these databases and March 2023. The primary outcomes included perioperative blood loss and blood transfusions. Secondary outcomes of interest included the length of stay (LOS) in hospital and the incidence of thromboembolic events. Weighted mean differences (WMDs) or odds ratios (OR) with 95% confidence intervals (CI) were used to determine treatment effects for continuous and dichotomous variables, respectively.
RESULTS: Five qualified studies including 307 thoracic surgical patients were included in the current study. Among them, 65 patients were randomly allocated to the group receiving TXA administration (the TXA group); the other 142 patients were assigned to the group not receiving TXA administration (the control group). TXA significantly reduced the quantity of hemorrhage in the postoperative period (postoperative 12h: WMD = -81.90 ml; 95% CI: -139.55 to -24.26; P = 0.005; postoperative 24h: WMD = -97.44 ml; 95% CI: -121.44 to -73.44; P< 0.00001); The intraoperative blood transfusion volume (WMD = -0.54 units; 95% CI: -1.06 to -0.03; P = 0.04); LOS in hospital (WMD = -0.6 days; 95% CI: -1.04 to -0.16; P = 0.008); And there was no postoperative thromboembolic event reported in the included studies.
CONCLUSIONS: The present study demonstrated that TXA significantly decreased blood loss within 12 and 24 hours postoperatively. A qualitative review did not identify elevated risks of safety outcomes such as thromboembolic events. It also suggested that TXA administration was associated with shorter LOS in hospital as compared to control. To validate this further, additional well-planned and adequately powered randomized studies are necessary.
Exemplary system and method are provided for affecting nail growth rate, which can use a light dosage and a wavelength of light to affect a growth rate of a nail of a subject. For example, it is possible to detect a presence of a nail using, e.g., a presence detector. The nail can be irradiated over a treatment time with a light having a wavelength and a power, e.g., using a narrowband light source. Further, using a controller, it is possible to control one or more of the power and the treatment time to irradiate the nail with a light dosage that is within a biphasic light dosage range bounded by a lesser light dosage and a greater light dosage. The wavelength of the light and the light dosage can be configured to affect a growth rate of the nail. Further, it is possible to document or record (e.g., to a computer file) and/or analyze at least one parameter related to the light dosage, e.g., possibly using the controller and/or a computer device.
PRECIS: This article delves into the imperative of screening family members of patients with glaucoma due to the disease's hereditary nature. It discusses the significant risks faced by first-degree relatives, approaches for identification, and challenges in implementing effective screening strategies. Emphasizing education, targeted campaigns, community involvement, and collaborative healthcare approaches, the article highlights the potential for mitigating undiagnosed glaucoma cases through strategic interventions targeting high-risk individuals.
PURPOSE: This article underscores the importance of screening family members of glaucoma patients, emphasizing the hereditary nature of the disease and the potential for screening to allow for early intervention to help prevent unnecessary vision loss.
METHODS/RESULTS: Glaucoma, affecting over 111.8 million by 2040, is relatively asymptomatic until late in the disease. Genetics predispose to glaucoma, with up to 70% heritability. High-risk individuals, particularly first-degree relatives, exhibit substantially elevated glaucoma risks-up to 22% compared with 2.3% in controls. Family history also correlates with greater disease severity. Identifying high-risk family members through cascade screenings for causative genes or direct examinations during proband visits emerges as efficient strategies. Challenges persist, including slow progression, healthcare accessibility, and ethical dilemmas in implementing family member screening. Challenges extend to the healthcare system, socioeconomic barriers, and familial communication issues. Efforts to educate probands and the public on the hereditary nature of glaucoma are pivotal. Tailored education campaigns, leveraging clinic visits, and community screenings, complemented by optometrist collaboration, form essential strategies.
CONCLUSIONS: Although challenges hinder family member screening, educating probands, targeted patient education, collaborative healthcare approaches, and community involvement offer promising avenues to combat undiagnosed glaucoma cases.
This group includes subjects with medical conditions placing them at an increased risk for meningococcal disease. Subjects will receive 2 doses of the investigational vaccine.
Low-dose (< 2 h/day), acute intermittent hypoxia (AIH) elicits multiple forms of serotonin-dependent phrenic motor plasticity and is emerging as a promising therapeutic strategy to restore respiratory and non-respiratory motor function after spinal cord injury (SCI). In contrast, high-dose (> 8 h/day), chronic intermittent hypoxia (CIH) undermines some forms of serotonin-dependent phrenic motor plasticity and elicits pathology. CIH is a hallmark of sleep disordered breathing, which is highly prevalent in individuals with cervical SCI. Interestingly, AIH and CIH preconditioning differentially impact phrenic motor plasticity. Although mechanisms of AIH-induced plasticity in the phrenic motor system are well-described in naïve rats, we know little concerning how these mechanisms are affected by chronic SCI or intermittent hypoxia preconditioning. Thus, in a rat model of chronic, incomplete cervical SCI (lateral spinal hemisection at C2 (C2Hx), we assessed serotonin type 2A, 2B and 7 receptor expression in and near phrenic motor neurons and compared: 1) intact vs. chronically injured rats; and 2) the impact of preconditioning with varied "doses" of intermittent hypoxia (IH). While there were no effects of chronic injury or intermittent hypoxia alone, CIH affected multiple receptors in rats with chronic C2Hx. Specifically, CIH preconditioning (8 h/day; 28 days) increased serotonin 2A and 7 receptor expression exclusively in rats with chronic C2Hx. Understanding the complex, context-specific interactions between chronic SCI and CIH and how this ultimately impacts phrenic motor plasticity is important as we leverage AIH-induced motor plasticity to restore breathing and other non-respiratory motor functions in people with chronic SCI.
The inventors have discovered that increased levels of intracellular zinc leads to cell death by apoptosis and necrosis. Surprisingly, p53 minus cells under cell death when treated with zinc. Thus, the invention is directed to zinc compositions useful in the targeted delivery of zinc compounds to cancer cells, to kill the cancer cells. Such compositions may contain targeted liposomes as the delivery vehicle. Likewise, the invention is directed to methods of killing cancer cells as well as treating cancer in a patient. The method involved delivering zinc-containing compositions to a cancer cell.
PURPOSE: To enhance decontaminatability and to impart rhombic dermatitis treatability by strongly emulsifying and dispersing 3.0 to 40 wt.% fats and oils and 0.02 to 2.0 wt.% amphoteric emulsifying agent in water, thereby preparing an emulsion. CONSTITUTION: The emulsion is prepd. by emulsifying and dispersing 3.0 to 40 wt.% fats and oils and 0.02 to 2.0 wt.% amphoteric emulsifying agent in the water. The more specific examples of the emulsifying agent include Carbopol 940, Carbopol 934, Carbopol 941, Carbopol 1342, octadecyne maleic anhydride copolymer, stearyl ethernuleic anhydride copolymer or the like. The more specific examples of the fats and oils include dimethycone, phenyldimethycone, stearoxydimethycone, cyclomethycone or the like. The amt. of the fats and oils to be added is adequately 27 to 33 wt.% and the amt. of the emulsifying agent to be added 0.8 to 1.4 wt.%.
The evolution of suppressed recombination between sex chromosomes is widely hypothesized to be driven by sexually antagonistic selection (SA), where tighter linkage between the sex-determining gene(s) and nearby SA loci is favored when it couples male-beneficial alleles to the proto-Y chromosome, and female-beneficial alleles to the proto-X. Although difficult to test empirically, the SA selection hypothesis overshadows several alternatives, including an incomplete but often-repeated "sheltering" hypothesis which suggests that expansion of the sex-linked region (SLR) reduces the homozygous expression of deleterious mutations at selected loci. Here, we use population genetic models to evaluate the consequences of partially recessive deleterious mutational variation for the evolution of otherwise neutral chromosomal inversions expanding the SLR on proto-Y chromosomes. Both autosomal and SLR-expanding inversions face a race against time: lightly-loaded inversions are initially beneficial, but eventually become deleterious as they accumulate new mutations, after which their chances of fixing become negligible. In contrast, initially unloaded inversions eventually become neutral as their deleterious load reaches the same equilibrium as non-inverted haplotypes. Despite the differences in inheritance and indirect selection, SLR-expanding inversions exhibit similar evolutionary dynamics to autosomal inversions over many biologically plausible parameter conditions. Differences emerge when the population average mutation load is quite high; in this case large autosomal inversions that are lucky enough to be mutation-free can rise to intermediate to high frequencies where selection in homozygotes becomes important (Y-linked inversions never appear as homozygous karyotypes); conditions requiring either high mutation rates, highly recessive deleterious mutations, weak selection, or a combination thereof.
Experimental Condition. Group-based, 8 weekly sessions/2 hours per week.
Bladder tumors are one of the most commonly diagnosed urinary tumors in the world. Worldwide, it has been estimated that 429,800 new cases of and 165,100 deaths due to bladder tumor occurred in 2012. Transurethral resection (TUR) is the gold-standard treatment for non-muscle invasive bladder cancer (NMIBC). In muscle-invasive bladder cancer, TUR also plays a vital role as a bladder-sparing procedure regardless of whether it is applied as a monotherapy or in combination with chemo-radiotherapy.

Whether radical resection of a tumor is initially performed can be essential in the treatment of bladder tumors. Incomplete TUR influences a patient's prognosis, regardless of whether it is part of a NMIBC treatment or part of bladder-sparing trimodal therapy. However, the quality of TUR is one of the greatest concerns in the treatment of bladder tumor. After initial TUR, approximately 70% of patients exhibit incomplete resection re-staging TUR. Of these patients, 30% exhibit residual tumors at the resection site. To solve this problem, a second TUR 4-6 weeks after the initial TUR is recommended by the guidelines, and these repeated TURs detect residual tumors in 26-83% of cases.

The investigators sought to identify other therapies that can be combined with TUR to eliminate residual tumors. As a minimally invasive method, cryotherapy has been widely used for urological tumors, including prostate tumor and kidney tumor. With respect to bladder tumors, cryotherapy remains in the exploration phase. Only a few studies of the use of computed tomography (CT)-guided percutaneous cryoablation for the treatment of bladder cancer have been reported. Unlike solid viscera, such as the prostate or kidney, the bladder exhibits the features of hollow viscera. Cryoablation through the transurethral approach could be possible if the safety of the procedure can be ensured. Our recent animal study conducted in a porcine model demonstrated the feasibility and safety of transurethral focal, full-thickness cryoablation. No perforations were observed during two eight-minute freeze cycles. Based on the success of transurethral cryoablation in animal experiments, the investigators performed this study to explore the safety and efficacy of cryoablation as an adjuvant therapy with TUR in the treatment of bladder tumors.
As technology advances, mobile devices have gradually turned into wearable devices. Furthermore, virtual reality (VR), augmented reality (AR), and mixed reality (MR) are being increasingly applied in medical fields such as medical education and training, surgical simulation, neurological rehabilitation, psychotherapy, and telemedicine. Research results demonstrate the ability of VR, AR, and MR to ameliorate the inconveniences that are often associated with traditional medical care, reduce incidents of medical malpractice caused by unskilled operations, and reduce the cost of medical education and training. What is more, the application of these technologies has enhanced the effectiveness of medical education and training, raised the level of diagnosis and treatment, improved the doctor-patient relationship, and boosted the efficiency of medical execution. The present study wants to design a training program for chemotherapy with using VR. Then the investigators design a protocol to compare the training effects in VR program and ISO document.
BACKGROUND: Clinical experience has shown that a single measure is not sufficient to assess disease activity in rheumatoid arthritis (RA). Various clinimetric tools are necessary to address the many clinical situations that can arise.
METHODS: In order to develop a comprehensive measurement tool, the Pan American League of Associations for Rheumatology searched for the most frequent measures of disease activity applied in RA by means of a semi-systematic review of the available literature.
RESULTS: We found that the most frequently reported measures of disease activity were the 28-joint Disease Activity Score, C-reactive protein, and the erythrocyte sedimentation rate, followed by patient-reported measures of pain and stiffness and many other composite indices and patient-reported outcome measures. The most frequent physician-reported sign of disease was the swollen joint count, and the most frequently self-reported feature was the increase in disease activity or flares.
CONCLUSION: In this article, we present a new clinimetric tool developed based on expert consensus and on data retrieved from our search. Disease activity can be better assessed by combining various data sources, such as clinical, laboratory, and self-reported outcomes. These variables were included in our novel clinimetric tool. Key Points • The goal of treatment of RA is to achieve the best possible control of inflammation, or even remission; therefore, disease management should include systematic and regular evaluation of inflammation and health status. • Clinimetric tools evaluate a series of variables (e.g., symptoms, functional capacity, disease severity, quality of life, disease progression) and can reveal substantial prognostic and therapeutic differences between patients. • Our clinimetric tool, which is based on a combination of data (e.g., clinical variables, laboratory results, PROMs), can play a relevant role in patient assessment and care.
Targeted muscle reinnervation (TMR) was originally developed as a means for increasing intuitive prosthesis control, though later found to play a role in phantom limb pain and neuroma prevention. There is a paucity of literature describing the clinical course of patients with poor TMR surgical outcomes and the value of imaging in the postoperative recovery period. This report will illustrate the potential utility of ultrasound neurography to accurately differentiate TMR surgical outcomes in two patients that received upper extremity amputation and subsequent reconstruction with TMR. Ultrasound evaluation of TMR sites in patient 1 confirmed successful reinnervation, evident by nerve fascicle continuity and eventual integration of the transferred nerve into the target muscle. Conversely, the ultrasound of patient 2 showed discontinuity of the nerve fascicles, neuroma formation, and muscle atrophy in all three sites of nerve transfer, suggesting an unsuccessful procedure and poor functional recovery. Ultrasound neurography is uniquely able to capture the longitudinal trajectory of rerouted nerves to confirm continuity and eventual reinnervation into muscle. Therefore, the application of ultrasound in a postoperative setting can correctly identify instances of failed TMR before this information would become available through clinical evaluation. Early identification of poor TMR outcomes may benefit future patients by fostering the discovery of failure mechanisms and aiding in further surgical planning to improve functional outcomes.
FIELD: medicine, curative cosmetology. SUBSTANCE: the innovation deals with manufacturing curative cosmetic products in the form of ointments, creams, emulsions, lotions, gels used as an antiedematous product. The suggested external antiedematous product contains a foundation, a target phosphonate additive, soluble magnesium salt. It, additionally, could contain medicinal and/or aromatizing and/or biologically active additives. EFFECT: higher efficiency. 2 cl
The pharmaceutical composition contains one or more pharmaceutical agents dissolved or uniformly suspended in a sheet whose material is soluble in water or organic solvents, preferably in both. It can be produced by dissolving or suspending the agent, introducing a sheet former which is soluble in water and/or soluble in organic solvents, drawing the resulting solution or suspension out to a film and drying the latter. The pharmaceutical sheet obtained in this way is divided into sections, e.g. dosage units. It is also possible to use release agents and fillers as well as the conventional flavourings, colorants etc. in the process.
[GB1510999A]